Noopept (Omberacetam)

Noopept is classified as a peptidomimetic — a small synthetic molecule that mimics the structure and function of peptides while offering the oral bioavailability advantages of a traditional small molecule drug. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester, and it contains the dipeptide backbone of proline-glycine. In the body, it is metabolized to cycloprolylglycine, an endogenous dipeptide that occurs naturally in the brain. So while Noopept itself is technically a modified dipeptide ester rather than a classical peptide, it functions as a prodrug that delivers a genuine neuropeptide (cycloprolylglycine) to the brain.

Noopept was specifically designed as a more potent alternative to piracetam and is approximately 1000 times more potent per milligram. Where piracetam is typically dosed at 2400-4800 mg per day, Noopept achieves comparable or superior effects at 10-30 mg per day. In direct laboratory comparisons using human cortical neurons, Noopept demonstrated significantly greater neuroprotective activity against oxidative damage than piracetam, and also outperformed vitamin E and other standard antioxidants. Additionally, Noopept has a broader mechanism of action — while piracetam primarily modulates glutamate receptors, Noopept also upregulates BDNF and NGF, provides anti-amyloid neuroprotection, and has cholinergic-positive effects.

Headaches are the most commonly reported side effect and are typically caused by choline depletion. Noopept enhances cholinergic neurotransmission, which increases the brain's demand for acetylcholine. If choline substrate is insufficient, this increased demand can cause headaches. The solution is straightforward: supplement with a bioavailable choline source such as Alpha-GPC (300-600 mg daily) or citicoline (250-500 mg daily). This is considered essential co-supplementation by most experienced Noopept users and typically resolves headaches completely.

Cycloprolylglycine (cyclo-Pro-Gly) is Noopept's primary active metabolite and an endogenous neuropeptide found naturally in the brain. It is a positive allosteric modulator of AMPA-type glutamate receptors — the primary receptors responsible for fast excitatory synaptic transmission, which underlies learning and memory formation. Cycloprolylglycine also stimulates BDNF expression through TrkB receptor-dependent mechanisms. This means Noopept essentially delivers a natural brain peptide through an orally bioavailable prodrug, providing a mechanism that works with the brain's own signaling systems rather than introducing a completely foreign compound.

Yes. Noopept (under its INN name omberacetam) is approved and prescribed as a nootropic medication in Russia and several neighboring countries. It is manufactured by JSC LEKKO Pharmaceuticals and available as 10 mg tablets. The standard Russian prescription regimen is 10 mg twice daily (20 mg total per day, maximum 30 mg) for courses of 1.5-3 months. It is not approved by the FDA or EMA, and in Western countries it is typically available as a research compound or dietary supplement.

Noopept has shown promising results in multiple preclinical Alzheimer's disease models. In in vitro studies, it protected cells against amyloid-beta toxicity by reducing oxidative stress, calcium overload, tau hyperphosphorylation, and mitochondrial apoptosis. In animal models, preventive administration completely prevented memory deficits caused by amyloid-beta injection into the basal nuclei, and therapeutic administration showed significant normalizing effects even when started well after neurodegenerative changes had developed. Researchers have noted that Noopept targets both common pathogenic pathways and disease-specific mechanisms of Alzheimer's pathology. However, these findings are from preclinical research — rigorous human clinical trials for Alzheimer's disease have not been completed.